delete The Medicines (Advertising) Amendment Regulations 1996
Amendment to Medicines (Advertising) Regulations 1994 that modifies advertising prohibition exceptions for certain medicinal products (neural tube defects, sprains/strains, rheumatic/non-serious arthritic conditions) and adds 'Joint, rheumatic and collagen diseases' to the Schedule 1 prohibited diseases list. Issued under authority of the Secretary of State for Health and sealed by DHSS for Northern Ireland.
This regulation restricts truthful commercial speech and information flow between medicine suppliers and consumers. Advertising restrictions of this kind: (1) paternalistically assume consumers cannot evaluate claims, protecting them 'from themselves'; (2) raise compliance costs for pharmaceutical companies, particularly disadvantages smaller competitors who lack legal departments; (3) prevent legitimate products for sprains, strains, and rheumatic conditions from competing effectively on their merits; (4) the prohibited diseases list creates ongoing regulatory uncertainty and compliance burden. The market, not regulators, should determine how companies communicate product information — fraud and false claims are already addressable under existing consumer protection law without restricting advertising itself.